Sickle Cell Disease Trial, Recruiting NCT07000747 Sponsor: Centre Hospitalier Universitaire de la Guadeloupe Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT07000747
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have sickle cell disease (specifically the SS or SC type), or you are a healthy person with normal hemoglobin (hemoglobin AA) who could join as a comparison volunteer
  • Your sickle cell disease was confirmed by a specialist lab test (such as electrophoresis or HPLC)
  • You are older than 6 years and younger than 25 years old at the time of joining the trial
  • You are currently in a stable, healthy period — meaning you have had no complications in the past month and no blood transfusions in the past three months
  • You are already receiving care for sickle cell disease at the sickle cell center at the University Hospital of Guadeloupe in Pointe-à-Pitre
  • You (or a parent/guardian if you are a minor) are willing and able to sign a written consent form agreeing to take part
  • You are covered by the national social security (health insurance) system
  • Healthy volunteers (with normal hemoglobin) may be recruited through posters displayed at the hospital

Who may not be able to join:

  • The exclusion criteria listed in this trial appear to mirror the inclusion criteria, which may be an error in the trial documentation — please confirm the specific reasons for exclusion directly with the trial site (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maryse Etienne-Julan, MD PhD, CHU de la Guadeloupe

Phone: +590590934677

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Registry
ClinicalTrials.gov
Start date
24 June 2024
Est. completion
24 June 2026

Where this trial is recruiting

Guadeloupe

Primary endpoints

Lymphocyte subpopulations measured by flow cytometry at steady-state

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov